Ablexis Garners $12,000,000 Series A Financing

  • Feed Type
  • Date
    6/2/2010
  • Company Name
    Ablexis
  • Mailing Address
    Undisclosed San Francisco, CA 94105
  • Company Description
    Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, was founded in December 2009, based on technology principles established by its subsidiary, Aliva Biopharmaceuticals, Inc.
  • Website
    http://www.ablexis.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $12,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    Proceeds from the financing will be used to continue advancing Ablexis’ proprietary AlivaMab Mouse transgenic mouse platform for the discovery of human therapeutic antibodies.
  • M&A Terms
  • Venture Investor
    Third Rock Ventures
  • Venture Investor
    Pfizer Strategic Investments Group

By posting a comment, you agree to our terms and conditions.